Neurotransmitter dysregulation in anorexia nervosa, bulimia nervosa, and binge eating disorder

Clinical Handbook of Eating Disorders: An Integrated Approach

Volumn , Issue , 2004, Pages 257-281

  Brewerton, Timothy D ^a   Steiger, Howard ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b DOUGLAS MENTAL HEALTH UNIVERSITY INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34248383894     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (165)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Press, 1994.
2. Becker AE, Grinspoon SK, Klibanski A, Herzog DB. Eating disorders. N Engl J Med 1999; 340:1092-1098.
3. Walsh BT, Devlin MJ. Eating disorders: progress and problems. Science 1998; 280:1387-1390.
4. Lilenfeld LR, Kaye WH, Greeno CG, Merikangas KR, Plotnicov K, Pollice C, Radhika R, Strober M, Bulik C, Nagy L. A controlled family study of anorexia nervosa and bulimia nervosa. Arch Gen Psychiatry 1998; 55:603-610.
5. Strober M, Freeman R, Lampert C, Diamond J, Kaye WH. Controlled family study of anorexia nervosa and bulimia nervosa: evidence of shared liability and transmission of partial syndromes. Am J Psychiatry 2000; 157:393-401.
6. Halmi KA, Sunday SR, Strober M, Kaplan A, Woodside DB, Fichter M, Treasure J, Berrettini WH, Kaye WH. Perfectionism in anorexia nervosa: variation by clinical subtype, obsessionality, and pathological eating behavior. Am J Psychiatry 2000; 157:1799-1805.
7. Kaye W, Strober M, Stein D, Gendall K. New directions in treatment research of anorexia and bulimia nervosa. Biol Psychiatry 1999b; 45:1285-1292.
8. Kaye WH, Gendall KA, Strober M. Serotonin neuronal function and selective reuptake inhibitor treatment in anorexia nervosa and bulimia nervosa. Biol Psychiatry 1998a; 44:825-838.
9. Brewerton TD. Toward a unified theory of serotonin dysregulation in eating and related disorders. Psychoneuroendocrinology 1995; 20:561-590.
10. Pollice C, Kaye WH, Greeno CG, Weltzin TE. Relationship of depression, anxiety, and obsessionality to state of illness in anorexia nervosa. Int J Eat Disord 1997; 21:367-376.
11. Cowen PJ, Clifford EM, Walsh AE, Williams C, Fairburn CG. Moderate dieting causes 5-HT2c receptor supersensitivity. Psychol Med 1996; 26:1155-1159.
12. Cowen PJ, Smith KA. Serotonin, dieting, and bulimia nervosa. Adv Exp Med Biol 1999; 467:101-104.
13. Goodwin GM, Fairburn CG, Cowen PJ. Dieting changes serotonergic function in women, not men: implications for the etiology of anorexia nervosa. Psychol Med 1987a; 17:839-842.
14. Goodwin GM, Fairburn CG, Cowen PJ. The effects of dieting and weight loss upon neuroendocrine responses to tryptophan, clonidine and apomorphine in volunteers: important implications for neuroendocrine investigations in depression. Arch Gen Psychiatry 1987b; 44:952-957.
15. Goodwin GM, Cowen PJ, Fairburn CG, Parry-Billings M, Calder PC, Newsholme EA. Plasma concentrations of tryptophan and dieting. Br Med J 1990; 300:1499-1500.
16. Deldago PL, Charney DS, Price LH, Aghajanian GK, Landis H, Henninger GR. Serotonin function and the mechanism of antidepressant action: reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry 1990; 47:411-418.
17. Kaye WH, Gendall KA, Fernstrom MH, Fernstrom JD, McConaha CW, Weltzin TE. Effects of acute tryptophan depletion on mood in bulimia nervosa. Biol Psychiatry 2000; 47:151-157.
18. Smith KA, Fairburn CG, Cowen PJ. Symptomatic relapse in bulimia nervosa following acute tryptophan depletion. Arch Gen Psychiatry 1999; 56:171-176.
19. Weltzin TE, Fernstrom MH, Fernstrom JD, Neuberger SK, Kaye WH. Acute tryptophan depletion and increased food intake and irritability in bulimia nervosa. Am J Psychiatry 1995; 152:1668-1671.
20. Rowland NE, Morien A, Li BH. The physiology and brain mechanisms of feeding. Nutrition 1996; 12:626-639.
21. Jimerson DC, George DT, Kaye W, Brewerton TD, Goldstein DS. Norepinephrine regulation in bulimia. In: Hudson JI, Pope HG, eds. Psychobiology of Bulimia. Washington, DC: American Psychiatric Press, 1987: 145-156.
22. Kaye WH, Gwirtsman HE, George DT, Jimerson DC, Ebert MH. CSF 5HIAA concentrations in anorexia nervosa: reduced values in underweight subjects normalize after weight gain. Biol Psychiatry 1988b; 23:102-105.
23. Kaye WH, Ballenger JC, Lydiard RB, Stuart GW, Laraia MT, O’Neil P, Fossey MD, Stevens V, Lesser S, Hsu G. CSF monoamine levels in normalweight bulimia: evidence for abnormal noradrenergic activity. Am J Psychiatry 1990; 147:225-229.
24. Kaye WH, George DT, Gwirtsman HE, Jimerson DC, Goldstein DS, Ebert MH, Lake CR. Isoproterenol infusion test in anorexia nervosa: assessment of pre- and post-beta-noradrenergic receptor activity. Psychopharmacol Bull 1990; 26:355-359.
25. Lesem MD, George DT, Kaye WH, Goldstein DS, Jimerson DC. State-related changes in norepinephrine regulation in anorexia nervosa. Biol Psychiatry 1989; 25:509-512.
26. Pirke KM. Central and peripheral noradrenalin regulation in eating disorders. Psychiatry Res 1996; 62:43-49.
27. Gross HA, Lake CR, Ebert MH, Ziegler MG, Kopin IJ. Catecholamine metabolism in primary anorexia nervosa. J Clin Endocrinol Metab 1979; 49:805-809.
28. Obarzanek E, Lesem MD, Goldstein DS, Jimerson DC. Reduced resting metabolicrateinpatientswithbulimianervosa. ArchGenPsychiatry 1991;48:456-462.
29. Halmi KA, Dekirmenjian H, Dav JM, Casper R, Goldberg S. Catecholamine metabolism in anorexia nervosa. Arch Gen Psychiatry 1978; 35:458-460.
30. Johnston JL, Leiter LA, Burrow GN, Garfinkel PE, Anderson GH. Excretion of urinary catecholamine metabolites in anorexia nervosa: effect of body composition and energy intake. Am J Clin Nutr 1984; 40:1001-1006.
31. Kaye WH, Ebert MH, Raleigh M, Lake CR. Abnormalities in CNS monoamine metabolism in anorexia nervosa. Arch Gen Psychiatry 1984; 41:350-355.
32. Kaye WH, Jimerson DC, Lake CR, Ebert MH. Altered norepinephrine metabolism following long-term weight recovery in patients with anorexia nervosa. Psychiatry Res 1985; 14:333-342.
33. Luck P, Mikhailid DP, Dashwood MR, Barradas MA, Sever PS, Dandona P, Wakeling A. Platelet hyperaggregability and increased alpha-adrenoceptor density in anorexia nervosa. J Clin Endocrinol Metab 1983; 57:911-914.
34. Pahl J, Pirke KM, Schweiger U, Warnhoff M, Gerlinghoff M, Brinkmann W, Berger M, Krieg C. Anorectic behavior, mood, and metabolic and endocrine adaptation to starvation in anorexia nervosa during inpatient treatment. Biol Psychiatry 1985; 20:874-887.
35. Kaye WH, Gwirtsman HE, George DT, Jimerson DC, Ebert MH, Lake CR. Disturbances of noradrenergic systems in normal weight bulimia: relationship to diet and menses. Biol Psychiatry 1990; 27:4-21.
36. Pirke KM, Jorg P, Schweiger U, Warnhoff M. Metabolic and endocrine indices of starvation in bulimia: a comparison with anorexia nervosa. Psychiatry Res 1985; 15:33-39.
37. Pirke KM, Kellner M, Philipp E, Laessle R, Krieg JC, Fichter MM. Plasma norepinephrine after a standardized test meal in acute and remitted patients with anorexia nervosa and in healthy controls. Biol Psychiatry 1992; 31:1074-1077.
38. Koo-Loeb JH, Pedersen C, Girdler SS. Blunted cardiovascular and catecholamine stress reactivity in women with bulimia nervosa. Psychiatry Res 1998; 80:13-27.
39. Pirke KM, Eckert M, Ofers B, Goebl G, Spyra B, Schweiger U, Tuschl RJ, Fichter MM. Plasma norepinephrine response to exercise in bulimia, anorexia nervosa, and controls. Biol Psychiatry 1989; 25:799-802.
40. Lonati-Galligani M, Pirke KM. Beta 2-adrenergic receptor regulation in circulating mononuclear leukocytes in anorexia nervosa and bulimia. Psychiatry Res 1986; 19:189-198.
41. Laessle RG, Schweiger U, Pirke KM. Mood and orthostatic norepinephrine response in anorexia nervosa. Psychiatry Res 1988; 24:87-94.
42. Biederman J, Herzog DB, Rivinus TM, Ferber RA, Harper GP, Onsulak PJ, Schildkrautt JJ. Urinary MHPG in anorexia nervosa patients with and without a concomitant major depressive disorder. J Psychiatr Res 1984; 18:149-160.
43. Kaye WH, George DT, Gwirtsman HE, Jimerson DC, Goldstein DS, Ebert MH, Lake CR. Isoproterenol infusion test in anorexia nervosa: assessment of pre- and post-beta-noradrenergic receptor activity. Psychopharmacol Bull 1990; 26:355-359.
44. George DT, Kaye WH, Goldstein DS, Brewerton TD, Jimerson DC. Altered norepinephrine regulation in bulimia: effects of pharmacological challenge with isoproterenol. Psychiatry Res 1990; 33:1-10.
45. Heufelder A, Warnhoff M, Pirke KM. Platelet alpha 2-adrenoceptor and adenylate cyclase in patients with anorexia nervosa and bulimia. J Clin Endocrinol Metab 1985; 61:1053-1060.
46. Buckholtz NS, George DT, Davies AO, Jimerson DC, Potter WZ. Lymphocyte beta-adrenergic receptor modification in bulimia. Arch Gen Psychiatry 1988; 45:479-182.
47. Gill J, DeSouza V, Wakeling A, Dandona P, Jeremy JY. Differential changes in alpha- and beta-adrenoceptor linked [45Ca2 +] uptake in platelets from patients with anorexia nervosa. J Clin Endocrinol Metab 1992; 74:441-446.
48. Engstrom G, Alling C, Blennow K, Regnell G, Traskman-Bendz L. Reduced cerebrospinal HVA concentrations and HVA/5-HIAA ratios in suicide attempters: monoamine metabolites in 120 suicide attempters and 47 controls. Eur Neuropsychopharmacol 1999; 9:399-405.
49. Hoebel BG. Brain neurotransmitters in food and drug reward. Am J Clin Nutr 1985; 42:1133-1150.
50. Jimerson DC, Lesem MD, Kaye WH, Brewerton TD. Low serotonin and dopamine metabolite concentrations in CSF from bulimic patients with frequent binge episodes. Arch Gen Psychiatry 1992; 49:132-138.
51. Kaye WH, Guido KWF, Frank GK, McConaha C. Altered dopamine activity after recovery from restricting anorexia nervosa. Neuropsychopharmacology 1999; 21:503-506.
52. Schultz W. Reward signaling by dopamine neurons. Neuroscientist 2001; 7:293-302.
53. Hoebel BG, Hernandez L, Schwartz DH, Mark P, Hunter GA. Microdialysis studies of brain norepinephrine, serotonin, and dopamine release during ingestive behavior. The Psychobiology of Human Eating Disorders. Ann N Y Acad Sci 1989; 575:71-193.
54. Dayan P, Balleine BW. Reward, motivation, and reinforcement learning. Neuron 2002; 36:285-298.
55. Dally P, Sargant W. Treatment and outcome of anorexia nervosa. Br Med J 1966; 2:793-795.
56. Vandereycken W, Pierloot R. Pimozide combined with behavior therapy in the shortterm treatment of anorexia nervosa. A double-blind placebo-controlled cross-over study. Acta Psychiatr Scand 1982; 66:445-450.
57. Vandereycken W. Neuroleptics in the short-term treatment of anorexia nervosa: a double-blind placebo-controlled, cross-over trial with sulpride. Br J Psychiatry 1984; 144:288-292.
58. Hansen L. Olanzapine in the treatment of anorexia nervosa. Br J Psychiatry 1999; 175:592.
59. Jensen VS, Mejlhede A. Anorexia nervosa: treatment with olanzapine. Br J Psychiatry 2000; 177:87.
60. LaVia M, Gray N, Kaye WH. Case reports of olanzapine treatment of anorexia nervosa. Int J Eat Disord 2000; 27:363-366.
61. Bruins-Slot L, Gorwood P, Bouvard M, Blot P, Ades J, Feingold J, Schwartz JC, Mouren-Simeoni MC. Lack of association between anorexia nervosa and D3 dopamine receptor gene. Biol Psychiatry 1998; 43:76-78.
62. Corcos M, Atger F, Levy-Soussan P, Avrameas S, Guilbert B, Cayol V, Jeammet P. Bulimia nervosa and autoimmunity. Psychiatry Res 1999; 87:77-82.
63. Kaye WH, Weltzin TE. Serotonin activity in anorexia and bulimia nervosa: relationship to the modulation of feeding and mood. J Clin Psychiatry 1991; 52 (suppl):41-48.
64. Dourish CT, Cooper SJ, Gilbert F, Coughlan J, Iversen SD. The 5-HT1A agonist 8-OH-DPAT increases consumption of palatable wet mash and liquid diets in the rat. Psychopharmacology 1988; 94:58-63.
65. De Vry J, Schreiber R. Effects of selected serotonin 5-HT(1) and 5-HT(2) receptor agonists on feeding behavior: possible mechanisms of action. Neurosci Biobehav Rev 2000; 24:341-353.
66. Brewerton TD, Murphy DL, Jimerson DC. Testmeal responses following mchlorophenylpiperazine and L-tryptophan in bulimics and controls. Neuropsychopharmacology 1994; 11:63-71.
67. Leibowitz SF, Alexander JT. Hypothalamic serotonin in control of eating behavior, meal size, and body weight. Biol Psychiatry 1998; 44:851-864.
68. Anderson IM, Mortimore C. 5-HT and human anxiety: evidence from studies using acute tryptophan depletion. Adv Exp Med Biol 1999; 467:43-55.
69. Kaye WH, Gwirtsman HE, George DT, Ebert MH. Altered serotonin activity in anorexia nervosa after long-term weight restoration. Arch Gen Psychiatry 1991a; 48:556-562.
70. Brewerton TD, Hand LD, Bishop ER. The Tridimensional Personality Questionnaire in eating disorder patients. Int J Eat Disord 1993; 14:213-218.
71. Waller DA, Gullion CM, Petty F, Hardy BW, Murdock MV, Rush AJ. Tridimensional Personality Questionnaire and serotonin in bulimia nervosa. Psychiatry Res 1993; 48:9-15.
72. Linnoila M, Virkhunen M, Scheinin M, Nuutila A, Rimon R, Goodwin FK. Low cerebrospinal fluid 5-hydroxyindoleacetic acid concentration differentiates impulsive from nonimpulsive violent behavior. Life Sci 1983; 33:2609-2614.
73. Coccaro EF, Siever LJ, Klar H, Maurer G, Cochrane K, Cooper TB, Mohr RC, Davis KL. Serotonergic studies in affective and personality disorder patients: correlates with suicidal and impulsive aggressive behavior. Arch Gen Psychiatry 1989; 46:587-599.
74. Brewerton TD, Stellefson EJ, Hibbs N, Hodges EJ, Cochrane CE. A comparison of eating disorder patients with and without compulsive exercising. Int J Eat Disord 1995; 17:413-416.
75. Epling F, Pierci D. Activity-based anorexia: a biological perspective. Int J Eat Disord 1988; 7:475-485.
76. Carlsson M, Svensson K, Eriksson E, Carlsson A. Rat brain serotonin: biochemical and functional evidence for a sex difference. J Neural Transm 1985; 63:297-313.
77. Goodwin GM, Fraser S, Stump K, Fairburn CG, Elliott JM, Cowen PJ. Dieting and weight loss in volunteers increases the number of alpha2adrenoceptors and 5-HT receptors on blood platelets without effect on [3H]imipramine binding. J Affect Disord 1987; 12:267-274.
78. Brewerton TD. Seasonal variation of serotonin function in humans: research and clinical implications. Ann Clin Psychiatry 1989; 1:153-164.
79. Brewerton TD, Berrettini W, Nurnburger J, Linnoila M. An analysis of seasonal fluctuations of CSF monoamines and neuropeptides in normal controls: findings with 5-HIAA and HVA. Psychiatry Res 1988; 23:257-265.
80. Goldbloom DS, Olmsted MP. Pharmacotherapy of bulimia nervosa with fluoxetine: assessment of clinically significant attitudinal change. Am J Psychiatry 1993; 50:770-774.
81. Raleigh MJ, McGuire MT, Brammer GL, Yuwiler A. Social and environmental influences on blood serotonin concentrations in monkeys. Arch Gen Psychiatry 1984; 41:405-410.
82. Raleigh MJ, Brammer GL, McGuire MT, Yuwiler A. Dominant social status facilitates the behavioral effects of serotonergic agonists. Brain Res 1985; 348:274-282.
83. McQuire MT, Raleigh MJ. Serotonin-behavior interactions in vervet monkeys. Psychopharmacol Bull 1985; 21:458-463.
84. Russell GF. The nutritional disorder in anorexia nervosa. J Psychosom Res 1967; 11:141-149.
85. Coppen AJ, Gupta RK, Eccleston EG, Wood KM, Wakeling A, de Sousa VF. Plasma tryptophan in anorexia nervosa. Lancet 1976; 1:961.
86. Hassanyeh F, Marshall EF. Measures of serotonin metabolism in anorexia nervosa. Acta Psychiatr Scand 1991; 84:561-563.
87. Askenazy F, Candito M, Caci H, Myquel M, Chambon P, Darcourt G, Puech AJ. Whole blood serotonin content, tryptophan concentrations, and impulsivity in anorexia nervosa. Biol Psychiatry 1998; 43:188-195.
88. Kaye WH, Ebert MH, Gwirtsman HE, Weiss SR. Differences in brain serotonergic metabolism between nonbulimic and bulimic patients with anorexia nervosa. Am J Psychiatry 1984; 141:1598-1601.
89. Gendall KA, Joyce PR. Meal-induced changes in tryptophan:LNAA ratio: effects on craving and binge eating. Eat Behav 2000; 1:53-62.
90. Gerner RH, Cohen DJ, Fairbanks L, Anderson GM, Young JG, Scheinin M, Linnoila M, Shaywitz BA, Hare TA. CSF neurochemistry of women with anorexia nervosa and normal women. Am J Psychiatry 1984; 141:948-949.
91. Gillberg C. Low dopamine and serotonin levels in anorexia nervosa. Am J Psychiatry 1983; 140:948-949.
92. Kaye WH. Persistent alterations in behavior and serotonin activity after recovery from anorexia and bulimia nervosa. Ann N Y Acad Sci 1997; 817:162-178.
93. Kaye W, Frank G. Gene-environment interactions: Brain and behavior in anorexia nervosa. Paper presented at the annual meeting of the Eating Disorder Research Society, November 20-23, 2002, Charleston, South Carolina.
94. Brewerton TD, Zealberg JL, Lydiard RB, Glover V, Sandler M, Ballenger JC. CSF isatin is elevated in bulimia nervosa. Biol Psychiatry 1995; 37:481-483.
95. Kaye WH, Greeno CG, Moss H, Fernstrom J, Fernstrom M, Lilenfeld LR, Weltzin TE, Mann JJ. Alterations in serotonin activity and psychiatric symptoms after recovery from bulimia nervosa. Arch Gen Psychiatry 1998; 55:927-935.
96. Brewerton TD, Brandt HA, Lesem DT, Murphy DL, Jimerson DC. Serotonin in eating disorders. In: Coccaro E, Murphy D, eds. Serotonin in Major Psychiatric Disorders. Washington, DC: American Psychiatric Press, 1990:153-184.
97. Brewerton TD, Jimerson DC. Studies of serotonin function in anorexia nervosa. Psychiatry Res 1996; 62:31-42.
98. Hadigan CM, Walsh BT, Buttinger C, Hollander E. Behavioral and neuro endocrine responses to metaCPP in anorexia nervosa. Biol Psychiatry 1995; 37:504-511.
99. Halmi KA, McBride PA, Sunday SR. Serotonin responsivity and hunger and satiety in eating disorders. Primary and Secondary Eating Disorders: A Psychoneuroendocrine and Metabolic Approach. Proceedings of the 2nd International Symposium on Disorders of Eating Behaviour, Pavia, Italy, September 15-19, 1992:123-131.
100. Monteleone P, Brambilla F, Bortolot F, La Rocca A, Maj M. Prolactin response to d-fenfluramine blunted in people with anorexia nervosa. Br J Psychiatry 1998; 172:439-442.
101. Monteleone P, Brambilla F, Bortolotti G, Maj M. Serotonergic dysfunction across the eating disorders: relationship to eating behaviour, purging behaviour, nutritional status and general psychopathology. Psychol Med 2000; 30:1099-1110.
102. Ward A, Brown N, Lightman S, Campbell IC, Treasure S. Neuroendocrine, appetitive and behavioural responses to d-fenfluramine in women recovered from anorexia nervosa. Br J Psychiatry 1998; 172:351-358.
103. Weizman R, Carmi M, Tyano S, Apter A, Rehavi M. High affinity [3H]imipramine binding and serotonin uptake to platelets of adolescent females suffering from anorexia nervosa. Life Sci 1986b; 38:1235-1242.
104. Zemishlany Z, Modai I, Apter A, Jerushalmy Z, Samuel E, Tyano S. Serotonin (5-HT) uptake by blood platelets in anorexia nervosa. Acta Psychiatr Scand 1987; 75:127-130.
105. Diaz-Marsa M, Carrasco JL, Hollander E, Cesar J, Saiz-Ruiz J. Decreased platelet monoamine oxidase activity in female anorexia nervosa. Acta Psychiatr Scand 2000; 101:226-230.
106. Finocchiaro LM, Polack E, Nahmod VE, Glikin GC. Cultured peripheral blood mononuclear leukocytes from anorexia nervosa patients are refractory to visible light. Life Sci 1995; 57:559-569.
107. Brewerton TD, Mueller EA, Lesem MD, Brandt HA, Quearry B, George DT, Murphy DL, Jimerson DC. Neuroendocrine responses to m-chlorophenylpiperazine and L-tryptophan in bulimia. Arch Gen Psychiatry 1992b; 49:852-861.
108. Levitan RD, Kaplan AS, Joffe RT, Levitt AJ. Hormonal and subjective responses to intravenous meta-chlorophenylpiperazine in bulimia nervosa. Arch Gen Psychiatry 1997; 54:521-527.
109. Steiger H, Gauvin L, Israel M, Koerner N, Ng Ying Kin NMK, Paris K, Young SN. Association of serotonin and cortisol indices with childhood abuse in bulimia nervosa. Arch Gen Psychiatry 2001; 58:837-843.
110. Steiger H, Young SN, Kin NM, Koener N, Israel M, Lageix P, Paris J. Implications of impulsive and affective symptoms for serotonin function in bulimia nervosa. Psychol Med 2001; 31:85-95.
111. Jimerson DC, Wolfe BE, Metzger ED, Finkelstein DM, Cooper TB, Levine JM. Decreased serotonin function in bulimia nervosa. Arch Gen Psychiatry 1997; 54:529-534.
112. McBride PA, Anderson GM, Khait VD, Sunday SR, Halmi KA. Serotonergic responsivity in eating disorders. Psychopharmacol Bull 1991; 27:365-372.
113. Monteleone P, Brambilla F, Bortolot F, Ferraro C, Maj M. Plasma prolactin response to D-fenfluramine blunted in bulimic patients with frequent binge episodes. Psychol Med 1998; 28:975-983.
114. Goldbloom DS, Garfinkel PE, Katz R, Brown GM. The hormonal response to intravenous 5-hydroxytryptophan in bulimia nervosa. J Psychosom Res 1996; 40:289-297.
115. Wolfe BE, Metzger ED, Levine JM, Finkelstein DM, Cooper TB, Jimerson DC. Serotonin function following remission from bulimia nervosa. Neuropsychopharmacology 2000; 22:257-263.
116. Fernstrom JD. Dietary effects on brain serotonin synthesis: relationship to appetite regulation. Am J Clin Nutr 1985; 42:1072-1082.
117. Kaye WH, Gwirtsman HE, Brewerton TD, George DT, Jimerson DC, Wurtman RJ. Bingeing behavior and plasma amino acids: a possible involvement of brain serotonin in bulimia. Psychiatry Res 1988; 23:31-43.
118. Kay WH, Frank GK, Meltzer CM, Price JC, McConaha CW, Crossan PJ, Klump K, Rhodes L. Altered serotonin 2A receptor activity in women who have recovered from bulimia nervosa. Am J Psychiatry 2001; 158:1152-1155.
119. Marazziti D, Macchi E, Rotondo A, Placidi GF, Cassano GB. Involvement of serotonin system in bulimia. Life Sci 1988; 43:2123-2126.
120. Hallman J, Sakurai E, Oreland L. Blood platelet monoamine oxidase activity, serotonin uptake and release rates in anorexia and bulimia patients and in healthy controls. Acta Psychiatr Scand 1989; 81:73-77.
121. Goldbloom DS, Hicks LK, Garfinkel PE. Platelet serotonin uptake in bulimia nervosa. Biol Psychiatry 1988; 28:644-647.
122. Steiger H, Leonard S, Kin NY, Ladouceur C, Ramdoyal D, Young SN. Childhood abuse and platelet tritiated-paroxetine binding in bulimia nervosa: implications of border line personality disorder. J Clin Psychiatry 2000; 61:428-435.
123. Asberg M, Schalling D, Träskman-Bendz L, Wägner A. Psychobiology of suicide, impulsivity and related phenomena. In: Meltzer HY, ed. Psychopharmacology:Third Generation of Progress. NewYork: Raven Press, 1987: 655-688.
124. Coccaro EF, Siever LJ, Klar HM, Cochrane K, Cooper TB, Mohs RC, Davis KL. Serotonergic studies in patients with affective and personality disorders: correlates with suicidal and impulsive aggressive behaviour. Arch Gen Psychiatry 1989; 46:587-599.
125. Swedo SE, Leonard HL, Krusei MJP, Rettew DC, Listwak SJ, Berrettini W, Stipetic M, Hamburger S, Gold PW, Potter WZ, Rapoport JL. Cerebrospinal fluid neurochemistry in children and adolescents with obsessive-compulsive disorder. Arch Gen Psychiatry 1992; 49:29-36.
126. Fineberg NA, Roberts A, Montgomery SA, Cowen PJ. Brain 5-HT function in obsessive-compulsive disorder. Prolactin responses to d-fenfluramine. Br J Psychiatry 1998; 171:280-282.
127. Altemus M, Swedo SE, Leonard HL, Richter D, Rubinow DR, Potter WZ, Rapaport JL. Changes in cerebrospinal fluid neurochemistry during treatment of obsessive-compulsive disorder with clomipramine. Arch Gen Psychiatry 1994; 51:846-849.
128. Germine RH, Goddard AW, Woods SW, Charnet DS, Henninger GR. Anger and anxiety response to ra-chlorophenylpiperazine in generalized anxiety disorder. Biol Psychiatry 1992; 32:457-461.
129. Mundo E, Bellodi L, Smeraldy E. Effects of acute intravenous clominpramine in obsessive-compulsive symptoms and response to chronic treatment. Biol Psychiatry 1995; 28:525-531.
130. Garvey MJ, Nowyes R Jr, Woodman C, Laukes C. Relationship of generalized anxiety symptoms to urinary 5-hydroxyindoleacetic acid and vanyllylmandelic acid. Psychol Res 1995; 57:1-5.
131. Askenazy F, Candito M, Caci H, Myquel M, Chambon P, Darcourt G, Puech AJ. Whole blood serotonin content, tryptophan concentrations, and impulsivity in anorexia nervosa. Biol Psychiatry 1998; 43:188-195.
132. Cloninger CR, Svrakic DM, Przybeck TR. A psychobiological model of temperament and character. Arch Gen Psychiatry 1993; 50:975-990.
133. Hollander E. Treatment of obsessive-compulsive spectrum disorder with SSRIs. Br J Psychiatry 1998; 35(suppl):7-12.
134. Waller DA, Sheinberg AL, Gullion C, Moeller FG, Cannon DS, Petty F, Hardy BW, Orsulak P, Ruch AJ. Impulsivity and neuroendocrine response to buspirone in bulimia nervosa. Biol Psychiatry 1996; 39:371-374.
135. Carrasco JL, Diaz-Marsa M, Hollander E, Cesar J, Saiz-Ruiz J. Decreased platelet monoamine oxidase activity in female bulimia nervosa. Eur Neuropsychopharmacol 2000; 10:113-117.
136. Steiger H, Koerner NM, Engleberg M, Israel M, Ng Ying Kin NMK, Young SN. Selfdestructiveness and serotonin function in bulimia nervosa. Psychiatry Res 2001; 103:15-26.
137. Coccaro EF, Kavoussi RJ, Sheline YI, Lish JD, Cszwenansky JG. Impulsive aggression in personality disorder correlates with tritiated paroxetine binding in the platelet. Arch Gen Psychiatry 1996; 53:531-536.
138. Simeon D, Stanley B, Frances A, Mann JJ, Winchel R, Stanley M. Selfmutilation in personality disorders: psychological and biological correlates. Am J Psychiatry 1992; 149:221-226.
139. Riedel WJ, Klaassen T, Deutz NE, van Someren A, van Praag HM. Tryptophan depletion in normal volunteers produces selective impairment in memory consolidation. Psychopharmacology 1999; 141:362-369.
140. Brewerton TD, Murphy DL, Mueller EA, Jimerson DC. The induction of migrainelike headaches by the serotonin agonist, w-chlorophenylpiperazine. Clin Pharmacol Ther 1988; 43:605-609.
141. Brewerton TD, Murphy DL, Lesem MD, Brandt HA, Jimerson DC. Headache responses to m-chlorophenylpiperazine and L-tryptophan in bulimia nervosa. Headache 1992; 32:217-222.
142. Spigset O, Andersen T, Hagg S, Mjondal T. Enhanced platelet serotonin 5HT2A receptor binding in anorexia nervosa and bulimia nervosa. Eur Neuropsychopharmacol 1999; 9:469-473.
143. Steiger H. Eating disorders and the serotonin connection: states, traits and developmental effects. J Psychiatry Neurosci. In press.
144. Hinney A, Remschimidt H, Hebebrand J. Candidate gene polymorphisms in eating disorders. Eur J Pharmacol 2000; 410:147-159.
145. Collier DA, Arranz MJ, Mupita D, Brown N, Treasure J. Association between the 5-HT2A receptor gene polymorphism and anorexia nervosa. Lancet 1997; 350: 412.
146. Nacmias B, Ricca V, Tedde A, Mezzani B, Rotella CM, Sorbi S. 5-HT2A receptor gene polymorphisms in anorexia nervosa and bulimia nervosa. Neurosci Lett 1999; 277:134-136.
147. Enoch MA, Kaye WH, Rotondo A, Greenberg BD, Murphy DL, Goldman D. 5-HT2A promoter polymorphism-1438G/A, anorexia nervosa, and obsessivecompulsive disorder. Lancet 1998; 351:1785.
148. Hinney A, Barth N, Ziegler A, vonPrittwitz S, Hamann A, Hennighausen K, Pirke KM, Heils A, Rosenkranz K, Roth H, Coners H, Mayer H, Herzog W, Siegfried A, Lehmkuhl G, Poustka F, Schmidt MH, Schafer H, Grzeschik KH, Lesch KP, Lentes KU, Remschmidt H, Hebebrand J. Serotonin transporter gene-linked polymorphic region, allele distributions in relationship to body weight and in anorexia nervosa. Life Sci 1997; 61:295-303.
149. Sundaramurthy D, Pieri LF, Gape H, Markham AF, Campbell DA. Analysis of serotonin transporter gene linked polymorphism (5-HTTLPR) in anorexia nervosa. Am J Med Genet 2000; 96:53-55.
150. Han L, Nielsen DA, Rosenthal NE, Jefferson K, Kaye W, Murphy D, Altemus M, Humphries J, Cassano G, Rotondo A, Virkkimen M, Linnoila M, Goldman D. No coding variant of the tryptophan hydroxylase gene detected in seasonal affective disorder, obsessive-compulsive disorder, anorexia nervosa, and alcoholism. Biol Psychiatry 1999; 45:615-619.
151. Hinney A, Herrmann H, Lohr T, Rosenkranz K, Ziegler A, Lehmkuhl G, Poustka F, Schmidt MH, Mayer H, Siegfried W, Remschmidt H, Hebebrand J. No evidence for an involvement of alleles of polymorphisms in the serotonin1Dbeta and 7 receptor genes in obesity, underweight or anorexia nervosa. Int J Obes Relat Metab Disord 1999; 23:760-763.
152. Ziegler A, Hebebrand J, Gorg R, Rosenkranz K, Fichter MM, HerpertzDahlmann B, Remschimidt H, Hinney A. Further lack of association between the 5-HT2A gene promoter polymorphism and susceptibility to eating disorders and a metaanalysis pertaining to anorexia nervosa. Mol Psychiatry 1999; 4:410-412.
153. Nishiguchi N, Matsuchita S, Suzuki K, Murayama M, Shirakawa O, Higuchi S. Association between 5HT2A receptor gene promoter region polymorphism and eating disorders in Japanese patients. Biol Psychiatry 2001; 50:123-128.
154. Di Bella DD, Catalano M, Cavallini MC, Riboldi C, Bellodi I. Serotonin transporter linked polymorphic region in anorexia nervosa and bulimia nervosa. Mol Psychiatry 2000; 5:233-241.
155. Heils A, Teufel A, Petri S, Stober G, Riederer P, Bengel D. Lesch KP: Allelic variations of human serotonin transporter gene expression. J Neurochem 1996; 66:2621-2624.
156. Bondy B, Erfurth A, de Jonge S, Kriiger M, Meyer H. Possible association of the short allele of the serotonin transporter promoter gene polymorphism (5HTTLPR) with violent suicide. Mol Psychiatry 2000; 5:193-195.
157. Lesch KP, Wolozin BL, Murphy DL, Reiderer P. Primary structure of the human platelet serotonin uptake site: identity with the brain serotonin transporter. J Neurochem 1993; 60:2319-2322.
158. Steiger H, Joober R, Israel M, Bruce K, NG Ying Kin NMK, Gauvin L, Young SN, Joncas J, Torkaman-Xehi A. A polymorphism in the promoter region of the serotonin transporter gene (5-HTTLPR) corresponds to impulsivity and reduced paroxetine binding in eating-disordered and normal-eater woman. Presented at the Annual Meeting of the Eating Disorders Research Society, Charleston, South Carolina, November 23, 2002.
159. Fluoxetine Bulimia Nervosa Collaborative Group. Fluoxetine in the treatment of bulimia nervosa: a multicenter, placebo-controlled, double-blind trial. Arch Gen Psychiatry 1992; 49:139-147.
160. Attia E, Haiman C, Walsh BT, Flater SR. Does fluoxetine augment the inpatient treatment of anorexia nervosa? Am J Psychiatry 1998; 155:548-551.
161. Strober M, Pataki C, Freeman R, DeAntonio M. No effect of adjunctive fluoxetine on eating behavior or weight phobia during the inpatient treatment of anorexia nervosa: an historical case-control study. J Child Adol Psychopharmacol 1999; 9:195-201.
162. Faris PL, Kim SW, Meller WH, Goodale RL, Hofbauer RD, Oakman SA, Howard LA, Stevens ER, Eckert ED, Hartman BK. Effect of ondansetron, a 5-HT3 receptor antagonist, on the dynamic association between bulimic behaviors and pain thresholds. Pain 1998; 77:297-303.
163. Faris PL, Kim SW, Meller WH, Goodale RL, Oakman SA, Hofbauer RD, Marshall AM, Daughters RS, Banerjee-Stevens D, Eckert ED, Hartman BK. Effect of decreasing afferent vagal activity with ondansetron on symptoms of bulimia nervosa: a randomised, double-blind trial. Lancet 2000; 355:792-797.
164. Roychoudhury M, Kulkarni SK. Anti-anxiety profile of ondansetron, a selective 5-HT3 antagonist, in a novel animal model. Methods Find Exp Clin Pharmacol 1997; 19:107-111.
165. Glover V, Halket JM, Watkins PJ, Clow A, Goodwin BL, Sandler M. Isatin: identity with the purified endogenous monoamine oxidase inhibitor tribulin. J Neurochem 1988; 51:656-659.